ET-traps limited - ET-traps is a novel therapeutic for sequestering pathologically elevated endothelin-1 (ET-1) levels in the body, which is associated with a number of diseases including cardiovascular atherosclerosis, chronic kidney disease, pulmonary arterial hypertension, cancer, diabetes and neurodegenerative disorders e.g. MS. Our patent has been granted in the US and EPO.
Dr Arjun Jain founded and incorporated ET-traps Limited in 2015 after winning the Biotech startup weekend organized by Judge Business School in association with AstraZeneca UK.
By binding only to the excess ET-1 in the body to bring it down to normal levels and not completely blocking the action of ET-1 in other physiological functions, ET-traps are efficacious in bringing different markers of kidney and heart function to non-disease levels while being non-toxic.
We have performed binding assays that confirmed the solubility of our ET-trap construct (an Fc fusion protein) and that it is a very potent binder to endothelin-1, with a binding affinity in the pico molar range. Furthermore, the dissociation of our ET-traps once bound to ET-1 is very slow.
We have successfully completed PoC studies in the diabetes disease space, which show that the ET-traps potently and significantly ameliorate disease pathology, including diabetic cardiomyopathy, diabetic kidney disease, and returns various markers of heart and kidney function to non-disease levels.
Furthermore, our PoC work (both in vitro and in vivo) has shown that ET-traps are non- toxic or cytotoxic at the working concentration, which gives efficacy with no side effects.